Search results
Results from the WOW.Com Content Network
Bausch Health. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders ...
Bausch & Lomb (since 2010 stylized as Bausch + Lomb[ 2]) is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, [ 3] lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. [ 4][ 5] The company was founded in Rochester ...
Title. Chairman and CEO, Emergent BioSolutions. Term. Feb 2024-. Board member of. Emergent BioSolutions. Children. 3. Joseph C. Papa (born October 1, 1955) is an American businessman and the chairman and chief executive officer (CEO) of Bausch & Lomb, a company formed from the initial public offering (IPO) of the eye health business of Bausch ...
Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would spin off the eye-care company.
On Thursday, Bausch Health Companies (NYSE:BHC) reported a second-quarter 2024 GAAP EPS of $0.03 compared to the consensus of $0.28. The company reported revenues of $2.403 billion, up 11% year ...
Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin-off its eye care unit Bausch + Lomb into a separate publicly listed company. Bausch Health, previously known as ...
Brent Saunders (1969 or 1970) is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb.He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie.
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.